A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain

Journal of Neurology

Volumn 262, Issue 1, 2015, Pages 27-40

  Hoggart, B ^a   Ratcliffe, S ^b   Ehler, E ^c   Simpson, K H ^d   Hovorka, J ^e   Lejcko J ^f   Taylor, L ^g   Lauder, H ^g   Serpell, M ^h  

^a SOLIHULL HOSPITAL   (United Kingdom)

^b MAC Clinical Research Cobra Court   (United Kingdom)

^c Pardubice Regional Hospital   (Czech Republic)

^d SEACROFT HOSPITAL   (United Kingdom)

^e Neuropsychiatrické a Epileptologické Centrum   (Czech Republic)

^f CHARLES UNIVERSITY   (Czech Republic)

^g Porton Down Science Park   (United Kingdom)

^h GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

Author keywords

Cannabidiol; Cannabinoid; Delta 9 tetrahydrocannabinol; Neuropathic pain; THC CBD spray

Indexed keywords

CANNABIDIOL PLUS DRONABINOL; CANNABINOID; PLACEBO; UNCLASSIFIED DRUG; ANALGESIC AGENT; CANNABIDIOL; DRONABINOL; DRUG COMBINATION; ORAL SPRAY;

ADULT; ALLODYNIA; ARTICLE; COMPLEX REGIONAL PAIN SYNDROME; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE SEVERITY; DISORIENTATION; DIZZINESS; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FATIGUE; FEMALE; HEADACHE; HUMAN; INFECTION; INFESTATION; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEBULIZATION; NERVE LESION; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL DISORDER; PERIPHERAL NEUROPATHIC PAIN; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SLEEP QUALITY; SOMNOLENCE; TREATMENT RESPONSE; VASCULAR DISEASE; VOMITING; XEROSTOMIA; AGED; ANALGESIA; CLINICAL TRIAL; COMPLICATION; DRUG COMBINATION; FOLLOW UP; HYPERALGESIA; MIDDLE AGED; NEURALGIA; ORAL SPRAY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANALGESICS; CANNABIDIOL; DIABETIC NEUROPATHIES; DRONABINOL; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERALGESIA; MALE; MIDDLE AGED; NEURALGIA; ORAL SPRAYS; PAIN MANAGEMENT; TREATMENT OUTCOME;

EID: 84926664277     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-014-7502-9     Document Type: Article

References (36)

1. Backonja M, Serra J (2004) Pharmacologic management part 1: better studied neuropathic pain diseases. Pain Medicine 5(Suppl 1):S28–S47
2. Jensen TS, Gottrup H, Sindrup SH, Bach FW (2001) The clinical picture of neuropathic pain. Eur J Pharmacol 429(1–3):1–11
3. Woolf CJ, Max BM (2001) Mechanism-based pain diagnosis. Anaesthesiology 95(1):241–249
4. Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74(2):129–180
5. Russo EB (2011) Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 163(7):1344–1364
6. Russo EB (2010) MHRA Public Assessment Report Decentralised Procedure, Sativex Oromucosal Spray, UK/H/2462/001/DC. http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con084961.pdf. Accessed 17 June 2014
7. Welch SP, Stevens DL (1992) Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J Pharmacol Exp Ther 262(1):10–18
8. Smith FL, Cichewicz D, Martin ZL, Welch SP (1998) The enhancement of morphine antinociception in mice by delta-9- tetrahydrocannabinol. Pharmacol Biochem Behav 60(2):559–566
9. Reche I, Fuentes JA, Ruiz-Gayo M (1996) Potentiation of delta-9-tetrahydrocannabinol-induced analgesia by morphine in mice: Involvement of mu- and kappa-opioid receptors. Eur J Pharmacol 318(1):11–16
10. Bushlin I, Rozenfeld R, Devi LA (2010) Cannabinoid-opioid interactions during neuropathic pain and analgesia. Curr Opin Pharmacol 10(1):80–86
11. Svendsen KB, Jensen TS, Bach FW (2004) Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 329(7460):253–260
12. Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U (2003) Analgesic effect of the synthetic cannabinoid CT3 on chronic neuropathic pain: A randomized controlled trial. JAMA 290(13):1757–1762
13. Rog DJ, Nurmikko TJ, Friede T, Young CA (2005) Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 65(6):812–819
14. Rog DJ, Nurmikko TJ, Young CA (2007) Oromucosal delta-9 tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther 29(9):2068–2079
15. Berman JS, Symonds C, Birch R (2004) Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: Results of a randomized controlled trial. Pain 112(3):299–306
16. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D (2007) Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebocontrolled clinical trial. Pain 133(1–3):210–220
17. Serpell MG, Ratcliffe S, Hovorka J, Schofield M, Taylor L, Lauder H, Ehler E (2014) A double-blind, randomized, placebocontrolled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. Eur J Pain. doi:10.1002/j.1532-2149.2013.00445.x
18. GW Pharmaceuticals Ltd. NCT00710424 (2000) A double blind, randomized, placebo controlled, parallel group study of Sativex in the treatment of subjects with pain due to diabetic neuropathy. In: ClinicalTrials.gov (Internet). Bethesda (MD): National Library of Medicine (US). http://clinicaltrials.gov/show/NCT00710424: NCT00710424 (cited 23 Oct 2013)
19. Committee for Medicinal Products for human use (CHMP) (2004) Guideline on clinical investigation of medicinal products intended for the treatment of neuropathic pain. London (CHMP/EWP/252/03)
20. Neuropathic pain scale PDF (2013) Practicing clinicians exchange. http://practicingclinicians.com/cms/wb/PCEv3/site/hs09_pdfs/nps.pdf. Accessed 02 October 2013
21. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM (2001) Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94(2):149–158
22. Attal N, Cruccua G, Haanpää M, Hansson P, Jensen TS, Nurmikko T, Sampaio C, Sindrup S, Wiffen P, EFNS Task Force (2006) EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 13(11):1153–1169
23. Abrams DI, Jay CA, Shade SB, Vizoso RN, Reda H, Press S, Kelly ME, Rowbotham MC, Petersen KL (2007) Cannabis in painful HIV-associated sensory neuropathy: a randomised placebo- controlled trial. Neurology 68(7):515–521
24. Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, Gamsa A, Bennett GJ, Collet JP (2010) Smoked cannabis for chronic neuropathic pain: A randomized controlled trial. CMAJ 182(14):E694–E701
25. Toth C, Mawani S, Brady S, Chan C, Liu C, Mehina E, Garven A, Bestard J, Korngut L (2012) An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain 153(10):2073–2082
26. Casarett D, Karlawish J, Sankar P, Hirschman K, Asch DA (2001) Designing pain research from the patient’s perspective: What trial endpoints are important to patients with chronic pain? Pain Med 2(4):309–316
27. Turk DC, Dworkin RH (2004) What should be the core outcomes in chronic pain clinical trials? Arthritis Res Ther 6(4):151–154
28. Dworkin RH, Turk DC, Farrar JT, Haythornewaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Wernicke J, Witter J, IMPACT (2005) Core Outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 113(1–2):9–19
29. Stacey BR, daCosta DiBonaventura M, Martin S, Bell CF (2010) Chronological characteristics of painful diabetic peripheral neuropathy. American Pain Society ASM, Abstract, Glenview 23
30. Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, Schoelles KM (2010) Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev 20(1):CD006605
31. Bernal M, Haro JM, Bernert S, Brugha T, de Graaf R, Bruffaerts R, Lépine JP, de Girolamo G, Vilagut G, Gasquet I, Torres JV, Kovess V, Heider D, Neeleman J, Kessler R, Alonso J, ESEMED/MHEDEA Investigators (2007) Risk factors for suicidality in Europe: Results from the ESEMED study. J Affect Disord 101(1–3):27–34
32. Tang NK, Crane C (2006) Suicidality in chronic pain: A review of the prevalence, risk factors and psychological links. Psychol Med 36(5):575–586
33. Dworkin RH, Gitlin MJ (1991) Clinical aspects of depression in chronic pain patients. Clin J Pain 7(2):79–94
34. Fisher BJ, Cutler R, Rosomoff HL, Rosomoff RS (1997) Chronic pain associated with depression: antecedent or consequence of chronic pain? A review. Clin J Pain 13(2):116–137
35. Kessler RC, Borges G, Walters EE (1999) Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Survey. Arch Gen Psychiatry 56(7):617–626
36. Yen S, Shea MT, Pagano M, Sanislow CA, Grilo CM, McGlashan TH, Skodol AE, Bender DS, Zanarini MC, Gunderson JG, Morey LC (2003) Axis I and Axis II disorders as predictors of prospective suicide attempts: Findings from the collaborative longitudinal personality disorders study. J Abnorm Psychol 112(3):375–381